For many employees, it can be hard to feel connected to their company, especially at huge corporations like Walmart. But in ...

Novo Nordisk's new CEO is set to face intense investor scrutiny this week as the Wegovy-maker shakes up its board and pursues ...

Hims & Hers continues to sell compounded semaglutide, the active ingredient in Novo’s Wegovy and Ozempic drugs, and these ...

Pfizer alleges Novo Nordisk is attempting to "catch and kill" Metsera, a company Pfizer was in the process of acquiring, in ...

Novo Nordisk NVO is scheduled to report its third-quarter 2025 results before the opening bell on Nov. 5, 2025. The Zacks ...

Novo Nordisk's new CEO, Mike Doustdar, is under significant pressure as the company contends with declining stock prices, ...

Leading global healthcare company Novo Nordisk announces the launch of Wegovy® in Hong Kong, now available at private clinics and selected pharmacies. Clinically proven for long-term weight management ...

Novo Nordisk made a surprise bid for Metsera to boost its weight-loss market lead, trading at just 12x 2026 EPS. Read why NVO ...

There’s plenty of reason to remain bullish on Novo Nordisk. Even with the challenges it has faced recently, the company ...

Novo Nordisk (NVO) recruits top healthcare analyst Michael Novod, a long time bull of the company, as head of its investor ...

Novo Nordisk is striving to maintain Medicaid reimbursement for its obesity drug, Wegovy, as several U.S. states face ...

The Wegovy and Ozempic maker’s offer comes after Pfizer last month agreed to a lower deal to acquire the Nasdaq-listed ...